Natalie B Collins, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
DNA Mismatch Repair | 2 | 2023 | 428 | 0.720 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 378 | 0.630 |
Why?
|
Glioma | 3 | 2024 | 3400 | 0.480 |
Why?
|
Fanconi Anemia | 2 | 2019 | 323 | 0.400 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3769 | 0.360 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 1 | 2008 | 50 | 0.320 |
Why?
|
Melanoma, Experimental | 2 | 2018 | 562 | 0.240 |
Why?
|
Tumor Escape | 2 | 2017 | 367 | 0.230 |
Why?
|
Off-Label Use | 1 | 2024 | 177 | 0.200 |
Why?
|
MutS Homolog 2 Protein | 1 | 2022 | 195 | 0.200 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2021 | 67 | 0.190 |
Why?
|
Inositol | 1 | 2022 | 215 | 0.190 |
Why?
|
Sarcoma, Synovial | 1 | 2022 | 150 | 0.180 |
Why?
|
Neoplasms | 4 | 2024 | 21895 | 0.180 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2019 | 97 | 0.160 |
Why?
|
Biliary Atresia | 1 | 2019 | 88 | 0.160 |
Why?
|
Immune Evasion | 1 | 2022 | 360 | 0.160 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2019 | 146 | 0.150 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 895 | 0.150 |
Why?
|
Rhabdomyosarcoma | 1 | 2020 | 359 | 0.140 |
Why?
|
Cell Cycle Proteins | 1 | 2008 | 3440 | 0.140 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2017 | 51 | 0.140 |
Why?
|
Herpesvirus 8, Human | 1 | 2019 | 255 | 0.140 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 323 | 0.140 |
Why?
|
Adenosine Deaminase | 1 | 2018 | 248 | 0.140 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2022 | 4515 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1136 | 0.130 |
Why?
|
Sarcoma, Kaposi | 1 | 2019 | 374 | 0.130 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 2012 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2024 | 3607 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1587 | 0.110 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2017 | 1338 | 0.110 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2410 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2870 | 0.100 |
Why?
|
Brain Neoplasms | 2 | 2023 | 8917 | 0.100 |
Why?
|
Child | 10 | 2024 | 79453 | 0.100 |
Why?
|
Cell Nucleus | 1 | 2020 | 2909 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1789 | 0.090 |
Why?
|
Genomics | 3 | 2024 | 5752 | 0.090 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3182 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2018 | 1895 | 0.090 |
Why?
|
Disease Progression | 2 | 2024 | 13433 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 4489 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2329 | 0.080 |
Why?
|
RNA | 1 | 2019 | 2712 | 0.080 |
Why?
|
Alkylating Agents | 1 | 2008 | 134 | 0.080 |
Why?
|
Mitomycin | 1 | 2008 | 262 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2019 | 2292 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 6029 | 0.070 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 1748 | 0.070 |
Why?
|
Immunoprecipitation | 1 | 2008 | 880 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2882 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2021 | 9258 | 0.060 |
Why?
|
Immunotherapy | 2 | 2018 | 4612 | 0.060 |
Why?
|
Humans | 17 | 2024 | 755800 | 0.060 |
Why?
|
Serine | 1 | 2008 | 830 | 0.060 |
Why?
|
DNA Damage | 2 | 2019 | 2413 | 0.060 |
Why?
|
Interferons | 2 | 2018 | 702 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5187 | 0.060 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 2024 | 123 | 0.060 |
Why?
|
Mice | 5 | 2022 | 80753 | 0.050 |
Why?
|
Young Adult | 3 | 2024 | 58041 | 0.050 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2024 | 166 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2022 | 18030 | 0.050 |
Why?
|
Mutation | 3 | 2024 | 29817 | 0.050 |
Why?
|
HeLa Cells | 1 | 2008 | 3097 | 0.050 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 12 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2024 | 79735 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2008 | 2182 | 0.050 |
Why?
|
Molecular Targeted Therapy | 2 | 2024 | 2789 | 0.050 |
Why?
|
Blotting, Western | 1 | 2008 | 5044 | 0.050 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 32 | 0.040 |
Why?
|
Animals | 6 | 2022 | 167168 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 13957 | 0.040 |
Why?
|
Freezing | 1 | 2020 | 299 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11609 | 0.040 |
Why?
|
Neurofibromatosis 1 | 1 | 2024 | 564 | 0.040 |
Why?
|
Inhibitor of Differentiation Protein 2 | 1 | 2019 | 32 | 0.040 |
Why?
|
Child, Preschool | 4 | 2024 | 41911 | 0.040 |
Why?
|
Ganciclovir | 1 | 2019 | 253 | 0.040 |
Why?
|
Vincristine | 1 | 2020 | 1030 | 0.040 |
Why?
|
Precancerous Conditions | 1 | 2024 | 972 | 0.040 |
Why?
|
Phosphorylation | 1 | 2008 | 8323 | 0.040 |
Why?
|
RNA Editing | 1 | 2018 | 153 | 0.040 |
Why?
|
Microtubule-Associated Proteins | 1 | 2022 | 1077 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2018 | 292 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2021 | 13231 | 0.040 |
Why?
|
SEER Program | 1 | 2022 | 1524 | 0.030 |
Why?
|
Oncogenes | 1 | 2022 | 1218 | 0.030 |
Why?
|
Chickens | 1 | 2019 | 856 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2019 | 15588 | 0.030 |
Why?
|
Rare Diseases | 1 | 2021 | 619 | 0.030 |
Why?
|
Prognosis | 3 | 2022 | 29430 | 0.030 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 232 | 0.030 |
Why?
|
Infant | 3 | 2024 | 35883 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39189 | 0.030 |
Why?
|
Adolescent | 4 | 2024 | 87249 | 0.030 |
Why?
|
Ubiquitination | 1 | 2019 | 1008 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8439 | 0.030 |
Why?
|
Female | 9 | 2024 | 388048 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2019 | 1632 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3589 | 0.030 |
Why?
|
Male | 8 | 2024 | 356684 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2018 | 1323 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6140 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 1990 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2021 | 2148 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2017 | 1240 | 0.020 |
Why?
|
Paclitaxel | 1 | 2019 | 1705 | 0.020 |
Why?
|
Base Sequence | 1 | 2022 | 12444 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2018 | 16794 | 0.020 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2018 | 1241 | 0.020 |
Why?
|
Inflammation | 2 | 2021 | 10720 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2020 | 6795 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 21796 | 0.020 |
Why?
|
Tissue Donors | 1 | 2019 | 2250 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3575 | 0.020 |
Why?
|
NF-kappa B | 1 | 2017 | 2480 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8014 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3501 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12928 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5613 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2017 | 5420 | 0.020 |
Why?
|
DNA | 1 | 2019 | 7225 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2020 | 14330 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9374 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26046 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5288 | 0.010 |
Why?
|
Adult | 3 | 2024 | 218056 | 0.010 |
Why?
|
Liver | 1 | 2019 | 7474 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16482 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2017 | 10056 | 0.010 |
Why?
|
Prospective Studies | 1 | 2023 | 54015 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 39975 | 0.010 |
Why?
|
Melanoma | 1 | 2017 | 5657 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6820 | 0.010 |
Why?
|
Risk Factors | 1 | 2022 | 73885 | 0.010 |
Why?
|
Aged | 1 | 2024 | 167433 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36071 | 0.010 |
Why?
|
Middle Aged | 1 | 2024 | 218133 | 0.010 |
Why?
|